Alnylam

Alnylam CEO Maraganore scored $7.8M in 2020 pay. Or was it $13.6M? Depends how you view the numbers
Fierce Pharma
Thu, 04/15/21 - 11:59 pm
John Maraganore
Alnylam
Pharma CEOs
executive pay
Biotech’s important clinical data readouts
EP Vantage
Fri, 03/26/21 - 10:35 am
biotech
Scholar Rock
apitegromab
spinal muscular atrophy
Alnylam
vutrisiran
Dicerna
nedosiran
Primary Hyperoxaluria
FDA
John Maraganore makes a bold promise ahead of #JPM21 — aiming to take Alnylam into the ranks of biotech's best
Endpoints
Mon, 01/11/21 - 10:41 am
Alnylam
Pharma CEOs
John Maraganore
JPMHC 2021
Alnylam's next-gen ATTR amyloidosis drug hits goals in phase 3, teeing up approval filing
Fierce Biotech
Thu, 01/7/21 - 11:33 am
clinical trials
Alnylam
ATTR amyloidosis
vutrisiran
FDA approves Alnylam's first-ever drug for rare kidney disease
Bizjournals
Tue, 11/24/20 - 10:41 am
Alnylam
FDA
kidney disease
Primary Hyperoxaluria
Decibel Therapeutics raises $82M as Laurence Reid looks to steer gene therapy pivot
Endpoints
Mon, 11/9/20 - 10:57 am
Decibel Therapeutics
Alnylam
Millennium
gene therapy
Alnylam makes case for lumasiran in infants ahead of FDA ruling
Fierce Biotech
Fri, 10/23/20 - 10:57 am
Alnylam
kidney disease
lumasiran
pediatric
FDA
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
Motley Fool
Sun, 10/18/20 - 08:32 pm
Alnylam
Vir Biotechnology
RNAi
vaccines
COVID-19
Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial
BioSpace
Thu, 10/1/20 - 11:28 am
Alnylam
lumasiran
clinical trials
Primary Hyperoxaluria
Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants
Fierce Biotech
Wed, 09/30/20 - 10:35 am
Alnylam
clinical trials
lumasiran
RNAi
PH1
Blackstone finalizes R&D pact with Alnylam as part of earlier $2 billion investment
Endpoints
Mon, 08/17/20 - 10:36 am
Blackstone
Alnylam
R&D
Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show
Fierce Pharma
Tue, 06/30/20 - 10:51 am
Alnylam
RNAi
Givlaari
acute hepatic porphyria
Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data
Endpoints
Sun, 06/7/20 - 10:32 pm
Alnylam
clinical trials
RNAi
lumasiran
PH1
Alnylam nabs speedy review, setting up 3rd possible approval in 3 years
Endpoints
Tue, 05/26/20 - 11:12 am
Alnylam
RNAi
FDA
drug approvals
lumasiran
hyperoxaluria
Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral
Fierce Biotech
Mon, 05/4/20 - 10:37 am
Alnylam
Vir Biotechnology
COVID-19
RNAi
clinical trials
Alnylam's vutrisiran gets fast-track treatment at the FDA
Fierce Biotech
Tue, 04/14/20 - 09:44 am
Alnylam
RNAi
FDA
hATTR
vutrisiran
fast track
Blackstone backs Alnylam with up to $2B investment
BioPharma Dive
Mon, 04/13/20 - 09:50 pm
generics
Alnylam
Blackstone
RNAi
Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1
Pharmaceutical Business Review
Wed, 04/8/20 - 10:51 am
Alnylam
Primary Hyperoxaluria
FDA
lumasiran
After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration
Endpoints
Mon, 04/6/20 - 10:29 am
Alnylam
Dicerna
John Maraganore
Douglas Fambrough
RNAi
Merck
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19
Pharmaceutical Business Review
Fri, 04/3/20 - 11:15 am
Vir Biotechnology
Alnylam
COVID-19
RNAi
drug development

Pages